Prospective Observational Study To Identify Patients With Advanced/Metastatic Nsclc And Alk Translocation And To Establish Their Therapeutic Management (Idealk)

Trial Profile

Prospective Observational Study To Identify Patients With Advanced/Metastatic Nsclc And Alk Translocation And To Establish Their Therapeutic Management (Idealk)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms IDEALK
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Aug 2016 Planned number of patients changed from 1 to 100.
    • 14 Jul 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top